Metoprolol is a potent cardioselective r-adrenoceptor blocking agent lacking intrinsic sympathomimetic activity and significant effects on the peripheral vascular bed (Ablad et al., 1973; Johnson, 1975) . We have previously studied the haemodynamic effects of metoprolol at rest and during exercise in normal subjects (Stenberg et al., 1975) . In the present study, we have investigated the effect of metoprolol on tachyarrhythmias of varying aetiology in patients with and without cardiac failure.
Subjects and methods
Forty-four consecutive patients, 30 men and 14 women, with various tachyarrhythmias were studied. Thirty-five had supraventricular and 9 had ventricular arrhythmias. The majority of the patients were between 20 and 40 years of age. Twenty-five patients suffered from rheumatic heart disease, 9 from ischaemic heart disease, and the remaining 10 had pericardial disease (2 cases), myocarditis (1 case), thyrotoxicosis (1 case) or idiopathic arrhythmias (6 cases). Twelve of the patients with supraventricular arrhythmias had atrial tachycardia, 5 had atrial flutter, and 18 had atrial fibrillation, in 3 combined with premature ventricular contractions. The patients with isolated ventricular arrhythmias included 7 with ventricular Received for publication 8 November 1976 premature contractions and 2 with ventricular tachycardia.
Patients with systolic blood pressure less than 80 mmHg, or with gross congestive heart failure, were excluded from the study, while those with mild congestive failure, bronchospasm, or signs of digitalis intoxication were included. Of 44 patients, 30 were receiving digitalis, and 9 of these had clinical and electrocardiographic evidence of digitalis intoxication. One patient had chronic obstructive lung disease, and 2 suffered from acute myocardial infarction.
It was difficult to assess the precise duration of arrhythmia in the patients with atrial fibrillation, atrial flutter, and ventricular premature beats, but from the history this was usually several months. The duration of atrial tachycardia was less than 4 hours in 4 patients, from 4 to 8 hours in 6 patients, and more than 8 hours in the other 2. Two patients with atrial tachycardia received the drug on two occasions with an interval of several days.
After an electrocardiographic diagnosis of the arrhythmia had been made, the electrocardiograms of the patients were continuously monitored. The study was said to have started when persistent arrhythmia had been observed over a period of at least 1 hour, during which time other antiarrhythmic drugs had been tried in several patients. Metoprolol was given intravenously in a dose of 0 15 mg per kg body weight at a rate of 1 mg per minute. The In 2 out of 3 patients with associated ventricular ectopic beats these disappeared after metoprolol. The degree of atrioventricular block increased in 4 of 5 patients with atrial flutter, thus decreasing the ventricular rate.
VENTRICULAR TACHYARRHYTHMIAS
Of 10 patients with ventricular ectopic beats, 6 became completely free from their arrhythmia after the administration of metoprolol (Table 3) , including 2 who were in atrial fibrillation (Table 1) . In 1 further patient the number of ectopic beats decreased significantly from 30 to 6 per minute.
One of the two patients with ventricular tachy--cardia reverted to normal sinus rhythm less than 5 minutes after the injection. This patient (case 1) was suffering from an acute myocardial infarction with shock, and his arrhythmia had previously failed to respond to lignocaine, procainamide, ajmaline, and practolol; no further fall of blood pressure was observed.
SIDE EFFECTS
No side effects were observed in any patient, and there were no significant changes in blood pressure. In patients with congestive heart failure, the pulmonary congestion did not increase, and there -was no deterioration in pulmonary function in the patient with chronic obstructive lung disease and junctional and ventricular ectopic beats. Discussion r-adrenoceptor blocking agents have become established drugs for the treatment of cardiac arrhythmias, and their use for this purpose has been extensively reviewed by Singh and Jewitt (1974) and Wit et al. (1975a, b, c) . Of the various Padrenoceptor blocking agents available propranolol has been most commonly used, and is of proven value in, for example, arrhythmias complicating acute myocardial infarction (Lemberg et al., 1970) . However, the drug has a significant negative inotropic action on the heart and may also cause bronchial constriction (Stephen, 1966) , and this will limit the use of propranolol in patients with manifest or threatening bronchospasm or cardiac failure. Such risks are considerably less with practolol, which also has a proven value as an antiarrhythmic agent (Gibson et al., 1968; Jewitt et al., 1969; Gent et al., 1970) . Unfortunately, however, practolol has the well-known drawback of causing severe immune reactions when used over prolonged periods (British Medical Journal, 1975) , and this has substantially limited its clinical usefulness.
Metoprolol, another cardioselective l-adrenoceptor blocking agent, has in earlier studies in animals and man been found to be a potent drug largely devoid of any influence on the smooth muscles of the bronchioles (Ablad et al., 1975) . Hence, this drug was used in the present study even in patients with pulmonary congestion, low arterial blood pressure, and airways obstruction. Metoprolol was found to be effective in all cases of paroxysmal atrial tachycardia, and produced significant decreases in heart rate in cases of atrial fibrillation and flutter. Cardiac rhythm was restored to normal in 3 out of 18 patients with atrial fibrillation. The number of patients with ventricular arrhythmias was small, but it is of interest to note that in 6 out of 10 cases the ventricular premature beats disappeared, and in one further patient a significant reduction in the frequency of ectopic beats was observed. Moreover, 1 of the 2 patients with ventricular tachycardia associated with shock secondary to acute myocardial infarction reverted to normal rhythm after previous failure to respond to administration of lignocaine, ajmaline, procainamide, and practolol.
Clinical experience with metoprolol in patients with cardiac arrhythmias has not previously been reported. In a similar study using practolol 5 out of 6 episodes of paroxysmal atrial tachycardia, and 4 out of 7 instances of ventricular ectopic beats re-sponded to practolol (Manjuran et al., 1977) . Thus, the results with practolol appear to be similar to those in the present study, but the number of patients in the former study was only 27.
Clinically, the use of metoprolol has so far been reported only in hypertensive patients (Bengtsson, 1976; Sannerstedt and Wasir, 1977) . In the present study, however, metoprolol was found to be a useful antiarrhythmic agent and virtually free from side effects. It may safely be given even to patients with congestive heart failure, signs of digitalis intoxication, and bronchial obstruction.
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